Integrating New Data From AIDS 2024: Pharmacist Perspectives

CCO Infectious Disease Podcast

المحتوى المقدم من Clinical Care Options, LLC and Clinical Care Options. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Clinical Care Options, LLC and Clinical Care Options أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

3M ago 18:22

MP3•منزل الحلقة

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

See the full program here.

413 حلقات

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv